Sarepta Names Ex-AbbVie R&D Chief Michael Severino as CEO

Price update August 27, 2026: SRPT closed at $21.59 on August 27 (Polygon), up 35.9% from the $15.89 July 27 close cited above. The stock rose roughly 11% on August 27 alone, continuing a multi-week recovery from the 91% drawdown. The recovery puts SRPT well above the levels discussed at publication.

Sarepta Therapeutics (NASDAQ: SRPT) appointed Michael Severino, M.D., as its new CEO effective July 28, 2026, succeeding Doug Ingram, who announced his retirement in February. Severino joins from Tessera Therapeutics, where he was CEO since 2022, and previously served as Vice Chair and President at AbbVie, where he oversaw the development of three multi-billion-dollar drugs: Rinvoq, Skyrizi, and Venclexta. He also held senior roles at Amgen as SVP of Development and Chief Medical Officer.

SRPT closed at $15.89 on July 27, down from a peak near $178 in December 2020, a 91% decline. The stock rose roughly 5.5% on the announcement.

Why Sarepta Needs a Scientific Leader

Sarepta is at a crossroads. Its flagship gene therapy Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy has faced commercial headwinds, including patient deaths in 2025 that led to a black box warning and the discontinuation of Sarepta’s internal gene therapy program. The company has pivoted toward siRNA technology in partnership with Arrowhead.

Meanwhile, Sarepta’s exon-skipping drugs Amondys 45 (casimersen) and Vyondys 53 (golodirsen) failed their confirmatory ESSENCE Phase 3 trial in November 2025. The primary endpoint, 4-step ascend velocity, missed statistical significance (p=0.309). Sarepta filed supplemental NDAs with the FDA seeking conversion from accelerated to traditional approval, supported by real-world evidence and safety data rather than the failed primary endpoint. The FDA accepted the applications with a PDUFA date of February 28, 2027.

Severino’s track record at AbbVie, where he led R&D through the development of three multi-billion-dollar drugs, signals the board wants a scientific leader to navigate these regulatory challenges and rebuild the pipeline. Ingram’s departure was motivated by personal reasons: two family members were diagnosed with myotonic dystrophy, another form of the disease Sarepta has spent its career treating.

The Regulatory Overhang

The Amondys 45 and Vyondys 53 PDUFA on February 28, 2027, is the next major catalyst. The FDA accepted the sNDAs despite the ESSENCE primary endpoint miss, which means the agency is willing to consider the totality of evidence. But accelerated approval conversions that rely on real-world evidence rather than a successful confirmatory trial are unusual. The FDA could require additional functional data, grant full approval, or withdraw the accelerated approvals entirely.

Sarepta’s 2025 total revenue was approximately $2.2 billion. Q1 2026 revenue was $730.8 million, down 1.9% year-over-year, with Elevidys contributing $102 million. The company guides $1.2 to $1.4 billion in 2026 revenue.

What to Watch

Q2 earnings on August 5 will be Severino’s first test. Analysts want to see Elevidys sales stabilization after the 2025 safety concerns and commercial restructuring. For broader context on the DMD competitive field, our analysis of Dyne’s z-rostudirsen BLA and the Capricor deramiocel FDA AdCom covers the challengers circling Sarepta’s franchise. Dyne’s drug produced 10x the dystrophin of Sarepta’s Exondys 51 in Phase 1/2 data, with monthly instead of weekly dosing.

The risk is straightforward: a new CEO does not change the ESSENCE data or the gene therapy safety record. What it can change is the company’s ability to execute on the regulatory strategy, rebuild the pipeline, and restore credibility with investors after a 91% stock decline. Severino starts Tuesday. The clock is already running on the February 28 PDUFA.

Source: Sarepta Therapeutics press release, July 27, 2026

What It Means for the Trade

A 35.9% August recovery to $21.59 says the market is giving Severino the benefit of the doubt, but the thesis is unchanged from the July depths: Sarepta is a February 28, 2027 PDUFA story wrapped in a turnaround narrative. The sNDAs for Amondys 45 and Vyondys 53 ask the FDA to convert accelerated approvals on real-world evidence after the confirmatory ESSENCE trial missed its primary endpoint outright (p=0.309) — an unusual ask with three possible outcomes, and the spread between full conversion and withdrawal is most of the equity value. Severino’s AbbVie pedigree (Rinvoq, Skyrizi, Venclexta) helps most where Sarepta is weakest: regulatory strategy and pipeline credibility with investors burned by a 91% drawdown. The dated catalysts are Q2 print trajectory under new leadership, Elevidys sales stabilization after the black box, and the February 28 decision itself; the competitive clock adds urgency, since Dyne’s z-rostudirsen and Capricor’s deramiocel are circling the same DMD patients.

Mechanism and Market Context

Sarepta’s franchise rests on exon-skipping: short oligonucleotides that splice around specific DMD gene mutations so patients produce a shorter but functional dystrophin. Amondys 45 and Vyondys 53 each address subsets of the mutation spectrum, and their accelerated approvals carried a confirmatory obligation the ESSENCE trial failed to meet on its primary functional endpoint — leaving the company arguing totality-of-evidence: real-world data and safety rather than the missed 4-step ascend velocity. That failure is the strategic reason for the Arrowhead siRNA pivot and the reason a development leader, not a commercial operator, got the CEO job. Elevidys, the Duchenne gene therapy, is the other lesson: patient deaths in 2025 brought a black box and the end of the internal gene-therapy program, compressing a one-time-treatment revenue model further. The DMD field’s next phase is being contested on durability and dosing burden — Dyne’s candidate produced roughly 10 times the dystrophin of Exondys 51 in early data with monthly rather than weekly dosing — so Sarepta’s conversion strategy is also a race to hold franchise position.

Risks and What Could Go Wrong

1. The February 28 FDA decision can go three ways, and withdrawal of the accelerated approvals is the tail scenario; real-world-evidence conversions without a successful confirmatory trial are rare.
2. Elevidys’ black box and safety record cap the launch trajectory regardless of who runs the company.
3. Competitors with better dystrophin data or dosing convenience could erode the exon-skipping base before any pipeline rebuild pays off.
4. The August rally repriced the turnaround ahead of evidence; a Q2 stumble under the new CEO would hit a stock that has already recovered on narrative alone.